PGC1 Antibody

What is PGC1 alpha and why is it important in research?

PGC1 alpha (PPAR-gamma Coactivator 1 alpha; also known as LEM6) is a 97-120 kDa member of the PGC-1 family of proteins. It plays crucial roles as a master regulator of mitochondrial biogenesis and function, and participates in both RNA processing and transcriptional coactivation in conjunction with multiple nuclear hormone receptors such as PPAR gamma, RAR, and TR. The protein is expressed in select cell types, including brown adipocytes, skeletal muscle, and hepatocytes, making it a significant target in metabolic, cardiovascular, and neurological disease research . Human PCG1 alpha is 798 amino acids in length and contains specialized domains including an LxxLL nuclear receptor binding motif, a PPAR-gamma interaction domain, nuclear localization signals, and an RNA binding/processing region .

What types of PGC1 antibodies are available for research applications?

Scientific research on PGC1 utilizes both monoclonal and polyclonal antibodies. Monoclonal antibodies like MAB10784 offer high specificity for human PGC1 alpha epitopes , while polyclonal antibodies such as NBP1-04676 are developed against recombinant proteins made to internal portions of the human PGC-1 alpha protein (typically within residues 400-550) . These antibodies have been validated across multiple species including human, mouse, rat, and sheep, making them versatile tools for comparative research across model organisms .

What is the typical subcellular localization of PGC1 alpha and how does this impact antibody selection?

PGC1 alpha primarily localizes to the nucleus when activated but can be cytoplasmic when inactive . This dynamic localization is important to consider when selecting antibodies for specific applications. For nuclear staining, antibodies must efficiently penetrate the nuclear membrane during sample preparation. When studying PGC1 alpha translocation between cellular compartments, researchers should select antibodies validated for detecting both nuclear and cytoplasmic forms to avoid false negative results in inactive states .

What are the recommended applications for PGC1 alpha antibodies?

PGC1 alpha antibodies have been validated for multiple applications including Western Blot (1-2 μg/ml), Immunocytochemistry/Immunofluorescence (1:1000), Immunohistochemistry (1:10-1:500), Chromatin Immunoprecipitation, Flow Cytometry (1-2.5 μg/ml), Immunoprecipitation, and Simple Western (1:25-1:80) . When performing immunohistochemistry on paraffin-embedded tissues, antigen retrieval with sodium citrate buffer (pH 6.0) is strongly recommended to unmask epitopes . For fluorescent detection in cell lines, antibodies can be used at concentrations of approximately 2-8 μg/mL followed by fluorophore-conjugated secondary antibodies .

How should sample preparation be optimized for PGC1 alpha detection?

For optimal detection of PGC1 alpha in tissue samples, heat-induced epitope retrieval is critical. When working with paraffin-embedded sections, researchers should subject tissue to heat-induced epitope retrieval using basic antigen retrieval reagents prior to incubation with primary antibodies . For cell lines, immersion fixation with 4% paraformaldehyde for 10 minutes followed by permeabilization in 0.5% Triton X-100 in PBS for 5 minutes has been successfully employed . When performing Western blot, reducing conditions and appropriate buffer systems (such as Western Blot Buffer Group 1) are recommended for detecting the expected band at approximately 145 kDa .

What controls should be included when using PGC1 alpha antibodies?

Rigorous experimental design requires appropriate controls. For PGC1 alpha antibodies, positive controls should include tissues known to express high levels of the protein, such as brown adipose tissue, skeletal muscle, or specific cell lines like Jurkat human acute T cell leukemia cells . Negative controls should include samples where PGC1 alpha expression is absent or knockdown validated samples . Additionally, researchers should consider using isotype controls and secondary-only controls to account for non-specific binding. Knockdown validation using siRNA or CRISPR techniques provides the most stringent validation of antibody specificity .

How can researchers distinguish between different PGC1 isoforms?

The PGC-1 family consists of three members: PGC-1α, PGC-1β, and PGC-1-related coactivator (PRC) . Additionally, tissue-specific isoforms of PGC-1α have been identified, particularly in neurological tissues . When designing experiments to distinguish between these isoforms, researchers should carefully select antibodies that target unique epitopes specific to each isoform. Western blotting with high-resolution gels can help separate closely related isoforms based on molecular weight differences. For more definitive identification, researchers might need to combine antibody-based techniques with mass spectrometry or RNA-based methods to confirm the specific isoform being detected . When studying specific tissue contexts, particularly in neurological or kidney research, validation that the selected antibody can detect tissue-specific variants is essential .

What factors affect PGC1 alpha detection in experimental systems?

Several factors can influence the detection of PGC1 alpha in experimental systems. PGC1 alpha activity is regulated by post-translational modifications, particularly phosphorylation. AMPK is known to phosphorylate Thr178 and Ser539, promoting cotranscriptional activity, while Akt-mediated phosphorylation at Ser571 downregulates PGC1 alpha activity . These modifications may affect epitope accessibility and antibody binding. Additionally, PGC1 alpha expression responds dynamically to physiological stimuli, meaning that experimental conditions (fasting, exercise, cold exposure) can significantly alter expression levels . Finally, fixation methods, antigen retrieval protocols, and antibody concentration all impact detection sensitivity and specificity .

How can PGC1 alpha antibodies be used to study mitochondrial dysfunction in disease models?

PGC1 alpha antibodies are valuable tools for studying mitochondrial dysfunction across various disease models. In renal diseases such as acute kidney injury and chronic kidney disease, researchers can use immunohistochemistry and Western blotting to correlate PGC1 alpha expression levels with mitochondrial function markers . Co-localization studies combining PGC1 alpha antibodies with mitochondrial markers can reveal spatial relationships between PGC1 alpha activity and mitochondrial biogenesis. In neurological disorders like Alzheimer's, Huntington's, and Parkinson's diseases, where mitochondrial dysfunction is a key pathological feature, PGC1 alpha antibodies can help track changes in expression and localization throughout disease progression . For quantitative assessment, researchers often combine antibody-based detection with functional assays of mitochondrial respiration or ROS production to establish mechanistic links between PGC1 alpha levels and mitochondrial health .

What considerations are important when using PGC1 antibodies in cancer research?

When investigating PGC1 alpha in cancer research, several considerations are important. Different cancer types show variable PGC1 alpha expression patterns, making proper tissue-matched controls essential . In liver cancer tissues, PGC1 alpha has been detected in nuclei of hepatocytes using immunohistochemistry techniques . For cancer cell lines, such as A431 human epithelial carcinoma or Jurkat human acute T cell leukemia lines, optimization of fixation and permeabilization protocols is crucial for accurate nuclear detection . Researchers should be aware that PGC1 alpha's role may vary between cancer types – in some contexts, it may promote tumor growth through metabolic adaptation, while in others, it may suppress tumor growth by promoting mitochondrial-dependent apoptosis . When studying tumor metabolism, combining PGC1 alpha antibody detection with metabolic flux analysis can provide insights into the functional consequences of altered PGC1 alpha expression .

How can ChIP experiments be optimized when using PGC1 alpha antibodies?

Chromatin Immunoprecipitation (ChIP) experiments with PGC1 alpha antibodies require careful optimization to identify DNA binding sites of this coactivator. Since PGC1 alpha functions primarily as a transcriptional coactivator rather than a direct DNA-binding protein, ChIP protocols should be optimized to capture protein-protein interactions between PGC1 alpha and its transcription factor partners . Cross-linking conditions should be adjusted to effectively capture these protein complexes (typically 1-2% formaldehyde for 10-15 minutes). Antibodies specifically validated for ChIP applications should be selected, as not all PGC1 alpha antibodies perform equally in this technique . Sonication conditions should be optimized to generate DNA fragments of appropriate size (200-500 bp). Positive controls should target genes known to be regulated by PGC1 alpha, such as mitochondrial biogenesis factors. For comprehensive analysis, ChIP-seq approaches can identify genome-wide binding patterns of PGC1 alpha complexes, particularly in response to physiological stimuli or disease conditions .

What approaches can be used to study post-translational modifications of PGC1 alpha?

Studying post-translational modifications (PTMs) of PGC1 alpha requires specialized approaches beyond standard antibody detection. Phosphorylation is a key regulatory mechanism for PGC1 alpha activity, with AMPK phosphorylating Thr178 and Ser539 to promote activity, while Akt-mediated phosphorylation at Ser571 downregulates activity . Researchers should use phospho-specific antibodies that target these key residues to monitor the activation state of PGC1 alpha. Immunoprecipitation followed by mass spectrometry can provide comprehensive mapping of multiple PTMs simultaneously. To establish functional significance, researchers can combine PTM detection with reporter assays measuring PGC1 alpha transcriptional activity. Pharmacological manipulation of kinases/phosphatases (AMPK activators, Akt inhibitors) coupled with PTM-specific antibody detection can reveal regulatory mechanisms. For in vivo relevance, researchers should examine how physiological stimuli known to activate PGC1 alpha (exercise, fasting, cold exposure) affect its PTM pattern in target tissues .

How can researchers investigate the interaction between PGC1 alpha and disease-causing genes in complex disorders?

Investigating interactions between PGC1 alpha and disease-causing genes requires multi-faceted approaches. For example, in kidney diseases, researchers have demonstrated that human nuclear factor 1B (HNF1B) directly controls mitochondria via PGC1 alpha . To investigate such relationships, researchers should employ co-immunoprecipitation studies using PGC1 alpha antibodies to identify protein-protein interactions with disease-relevant factors. Chromatin immunoprecipitation can determine whether disease-associated transcription factors bind to the PGC1 alpha promoter, as demonstrated for HNF1B in kidney cells . Genetic approaches using conditional knockout or knockdown models for both PGC1 alpha and the disease gene of interest can reveal functional relationships. In vitro reporter assays can quantify how disease-associated mutations affect PGC1 alpha transcriptional activity. For translational relevance, researchers should examine patient samples with disease-causing mutations to assess PGC1 alpha expression and activity, as demonstrated in HNF1B-mutant patient samples showing decreased PGC1 alpha expression . Integration of these approaches can establish mechanistic links between PGC1 alpha and disease pathogenesis.

Table 1: Recommended Applications and Conditions for PGC1 Alpha Antibody Use

Table 2: PGC1 Alpha Expression and Function in Disease Models